Ovarian Cancer Clinical Trial
Official title:
A Cancer Research UK Randomised, Multicentre, Phase II Trial of the DNAhypomethylating Agent, 5-Aza-2'-Deoxycytidine (Decitabine) Given Intravenously in Combination With Carboplatin, Versus Carboplatin Alone Given 4 Weekly in Patients With Progressive, Advanced Ovarian Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and decitabine, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It
is not yet known whether carboplatin is more effective with or without decitabine in
treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary
peritoneal cancer.
PURPOSE: This randomized phase II trial is studying carboplatin and decitabine to see how
well they work compared with carboplatin alone in treating patients with progressive,
advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
OBJECTIVES:
Primary
- To compare the response rate in patients with progressive, advanced ovarian epithelial
cancer, fallopian tube cancer, or primary peritoneal cancer who have methylated hMLH1
DNA in plasma treated with carboplatin with vs without decitabine.
Secondary
- To compare the response rate in all patients (regardless of methylation status) treated
with these regimens.
- To compare the progression-free survival and overall survival of patients treated with
these regimens.
- To compare the safety and tolerability of these regimens.
- To determine the feasibility of combining decitabine with carboplatin.
- To determine the incidence of hypersensitivity reactions to carboplatin.
- To study the relationship between peak plasma levels of decitabine and global or CpG
island specific methylation.
- To study the relationship between global and gene specific methylation in peripheral
blood mononuclear cells and response.
Tertiary
- To correlate the methylation status of genes associated with drug resistance detected
in plasma DNA with response.
- To determine the sensitivity and specificity of methylation of genes associated with
drug resistance detected in plasma DNA as a predictor of methylation status in tumor
cells isolated from ascites or tumor biopsy.
- To study methylation and expression of genes in tumor cells isolated from ascites or
tumor biopsy before and after treatment with decitabine and/or carboplatin.
- To investigate any correlation between methylation and expression of genes in surrogate
tissues, body fluids, or tumor cells and response or progression-free survival.
- To examine markers of cell death in plasma.
- To compare the methylation in tumor taken at the time of presentation vs at the time of
treatment.
OUTLINE: This is a multicenter study. Patients are stratified according to prior first-line
treatment (platinum alone vs platinum and taxane vs platinum and other combination), WHO
performance status (0 vs 1 vs 2), measurable disease criteria (RECIST criteria vs CA-125
criteria vs both), participating center, and the number of prior platinum-based regimens (1
vs 2). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive carboplatin IV over 30-60 minutes on day 1.
- Arm II: Patients receive decitabine IV over 6 hours on day 1 and carboplatin IV over
30-60 minutes on day 8.
In both arms, treatment repeats every 28 days for up to 8 courses in the absence of disease
progression or unacceptable toxicity.
Patients undergo blood sample collection periodically for pharmacodynamic studies. Samples
are assessed for methylation of hMLH1 by methylation-specific PCR; global DNA methylation by
high performance liquid chromatography (HPLC) ; methylation of the MAGE-1A gene promoter by
methylation-specific PCR or bisulfite pyrosequencing; and markers of apoptosis by ELISA.
Pharmacokinetic studies of decitabine are also performed using blood samples from patients
randomized to arm II. Ascitic fluid and/or tumor tissue samples may also be collected for
pharmacodynamic studies.
After completion of study treatment, patients are followed at 28 days and then every 2
months thereafter.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
;
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |